GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

A Study of LY3437943 in Healthy Participants With a High Body Mass Index

Effect of Injection Site on the Relative Bioavailability of a Single Dose of LY3437943 in Healthy Participants With a High Body Mass Index

Lead sponsor

Eli Lilly and Company

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers, Obesity / overweight

Key I/E criteria

•BMI 27-45•Healthy volunteers

Primary endpoint

•Part

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05959096

Org study ID18532

Secondary IDJ1I-MC-GZBSEli Lilly and Company

Timeline

Milestones

Study start2023-07-18actual

Study first posted2023-07-25actual

Primary completion2024-07-25actual

Study completion2024-07-25actual

Last update posted2024-10-01actual

Assets

Investigational agents

Retatrutide

Study populations

Who this study enrolls

Healthy volunteersObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Healthy males or females of nonchildbearing potential as determined by medical history, physical examination, and other screening procedures

•Body mass index (BMI) between 27.0 and 45.0 kilograms per meter squared (kg/m²), inclusive

•Are agreeable to receiving study treatment by injections under the skin or through a vein.

Exclusion criteria

•Have a history of diabetes (except gestational diabetes) or current diagnosis of diabetes (any form)

•Have a significant history of, or presence of, any of the following disorders capable of significantly altering the absorption, metabolism, or elimination of drugs

•Have known allergies to LY3437943, related compounds, or any components of the formulation

•Smoke more than 10 cigarettes or use the equivalent tobacco, smoking-cessation products, nicotine-containing products, or e cigarettes (nicotine and non nicotine) per day.

•Is a known user of drugs of abuse

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

4 endpoints

Primary/protocol endpoint

Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943

Time frame:Predose on Day 1 up to 43 days postdose (Part A)

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

Part A: PK: Maximum Concentration (Cmax) of LY3437943

Time frame:Predose on Day 1 up to 43 days postdose (Part A)

Cmax

concentration, descriptive

Secondary/protocol endpoint

Part B: PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943

Time frame:Predose on Day 1 up to 71 days postdose (Part B)

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Part B: PK: Maximum Concentration (Cmax) of LY3437943

Time frame:Predose on Day 1 up to 71 days postdose (Part B)

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.